Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
Ascendis Pharma (Nasdaq: ASND) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
Interested participants can access the live webcast or register for the teleconference through the company's website. A replay will be available in the Investors & News section at investors.ascendispharma.com for 30 days following the event.
Ascendis Pharma (Nasdaq: ASND) ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per giovedì 1 maggio 2025, dopo la chiusura dei mercati statunitensi. La società terrà una conference call e una diretta web alle 16:30 ora della costa orientale degli Stati Uniti nello stesso giorno.
Gli interessati potranno seguire la diretta web o registrarsi per la teleconferenza tramite il sito web dell'azienda. Una registrazione sarà disponibile nella sezione Investitori e Notizie all'indirizzo investors.ascendispharma.com per 30 giorni dopo l'evento.
Ascendis Pharma (Nasdaq: ASND) ha programado el anuncio de los resultados financieros del primer trimestre de 2025 y una actualización empresarial para el jueves 1 de mayo de 2025, después del cierre del mercado estadounidense. La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m., hora del Este, el mismo día.
Los interesados pueden acceder a la transmisión en vivo o registrarse para la teleconferencia a través del sitio web de la empresa. Una grabación estará disponible en la sección de Inversores y Noticias en investors.ascendispharma.com durante 30 días después del evento.
Ascendis Pharma (나스닥: ASND)는 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 1일 목요일 미국 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
관심 있는 참가자는 회사 웹사이트를 통해 라이브 웹캐스트에 접속하거나 전화회의 등록을 할 수 있습니다. 행사 후 30일간 investors.ascendispharma.com의 투자자 및 뉴스 섹션에서 다시보기가 제공됩니다.
Ascendis Pharma (Nasdaq : ASND) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 ainsi qu'une mise à jour commerciale pour le jeudi 1er mai 2025, après la clôture des marchés américains. La société organisera une conférence téléphonique et une webdiffusion à 16h30, heure de l'Est, le même jour.
Les participants intéressés peuvent accéder à la webdiffusion en direct ou s'inscrire à la téléconférence via le site internet de l'entreprise. Un replay sera disponible dans la section Investisseurs & Actualités sur investors.ascendispharma.com pendant 30 jours après l'événement.
Ascendis Pharma (Nasdaq: ASND) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Geschäftsupdate für Donnerstag, den 1. Mai 2025, nach Börsenschluss in den USA geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Interessierte Teilnehmer können den Live-Webcast verfolgen oder sich über die Unternehmenswebsite für die Telefonkonferenz anmelden. Eine Aufzeichnung wird im Bereich Investoren & Nachrichten auf investors.ascendispharma.com für 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (ii) Ascendis’ application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © April 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Scott Smith | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
FAQ
When will Ascendis Pharma (ASND) release Q1 2025 earnings?
What time is Ascendis Pharma's (ASND) Q1 2025 earnings call?
How can investors access Ascendis Pharma's Q1 2025 earnings webcast?
How long will Ascendis Pharma's Q1 2025 earnings call replay be available?
